Figure 1From: A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcomaKaplan–Meier curve of progression-free survival (days) for patients with advanced leiomyosarcoma (n = 44). Median progression free survival 7.1 months (95% CI 5.7–8.3 months).Back to article page